Polymerase Chain Reaction (PCR) - Articles and news items

Application note: Direct PCR from blood using Platinum SuperFi DNA Polymerase

Application note: Direct PCR from blood using Platinum SuperFi DNA Polymerase

Whitepapers / 14 December 2016 / Thermo Fisher Scientific

This application note describes how researchers can successfully perform PCR from blood samples without DNA purification using Platinum SuperFi DNA Polymerase…

Whitepaper: Maintaining sample integrity with aerosol-blocking tips

Whitepaper: Maintaining sample integrity with aerosol-blocking tips

Whitepapers, Z Homepage promo / 7 October 2016 / Thermo Fisher Scientific

In this whitepaper, find out more about maintaining sample integrity with aerosol-blocking tips…

New England Biolabs (UK) Ltd

New England Biolabs® launches NEBNext Direct™ Technology with Cancer HotSpot Panel

Supplier news / 8 August 2016 / New England Biolabs, Inc.

Novel target enrichment technology, compatible with low input amounts from challenging sample types, uses a one-day workflow…

Whitepaper - Chimera Biotec - April 2016

Whitepaper: Bioanalytical support in the development of biologics

Whitepapers, Z Homepage promo / 1 April 2016 / Chimera Biotec

In this publication Imperacer® case studies demonstrate the advantage of broad assay range combined with excellent sensitivity for several Biologics on their way from R&D to clinics…

MIQE compliance in expression profiling and clinical biomarker discovery

MIQE compliance in expression profiling and clinical biomarker discovery

Cancer Biology, Issue 6 2015 / 6 January 2016 / Irmgard Riedmaier, Melanie Spornraft, Benedikt Kirchner and Michael W. Pfaffl, Technical University of Munich

Molecular diagnostics and biomarker discovery are gaining increasing attraction in clinical research. This includes all fields of diagnostics, such as risk assessment, disease prognosis, treatment prediction and drug application success control. The detection of molecular clinical biomarkers is very widespread and can be developed on various molecular levels, like the genome, the epi-genome, the transcriptome, the proteome or the metabolome. Today, numerous high-throughput laboratory methods allow rapid and holistic screening for such marker candidates. Regardless of which molecular level is analysed, in order to detect biomarker candidates, high sample quality and a standardised and highly reproducible quantification workflow are prerequisites. This article describes an optimal and approved development strategy to discover and validate ‘transcriptional biomarkers’ in clinical diagnostics, which are in compliance with the recently developed MIQE guidelines. We focus on the importance of sample quality, RNA integrity, available screening and quantification methods, and biostatistical tools for data interpretation…

PCR in-depth focus 2015

PCR in-depth focus 2015

Genomics, Issue 3 2015, Supplements / 3 July 2015 / European Pharmaceutical Review

In this PCR in-depth focus: Mikael Kubista from TATAA Biocenter addresses biological heterogeneity with single cell profiling, a look at quantitative PCR in the assessment of novel hepatic cell models, plus Q&A with Bio-Rad’s Javier Alba…

The evolving field of PCR

The evolving field of PCR : which method will you choose?

Issue 6 2014 / 23 December 2014 / Natalia Meani and Manuela Vecchi

Recognised as one of the major scientific breakthroughs of the 20th century, polymerase chain reaction (PCR) is a quick and simple method to create, in a test tube, millions of copies of a given DNA segment from a complex mixture of genetic material. This method has greatly stimulated biochemical, molecular biology and genetic research and, given its ability to amplify DNA from limited amounts of biologic samples, including fossils, opened the way for new applications in medicine, genetics, biotechnology, forensics and paleobiology…

PCR Supplement 2013

PCR: In-depth focus 2013

Genomics, Issue 5 2013, Supplements / 25 October 2013 / Martina Weber (Emory University) / Billy Lau & Hanlee Ji (Stanford University School of Medicine)

Challenges for qRT-PCR in detecting / quantifying microRNA in vitro and in vivo.
Emerging clinical applications of digital PCR.
Workshop Preview: Advanced 3d cell based assays, preparation, analysis and troubleshooting.


resDNASEQ® E. coli Residual DNA Quantitation System

News, Supplier news / 1 June 2012 / Life Technologies

Integrated sample preparation and real-time PCR assay for the quantitation of E. coli host cell DNA…

The evolving field of PCR

Building robust PCR/qPCR assays

Genomics, Issue 2 2012 / 26 April 2012 / Linda Starr-Spires, Director, Nucleic Acid Methods Platform, Global Clinical Immunology Department, Sanofi Pasteur

The process of building robust PCR/qPCR assays is a matter of perseverance and consistency. A few questions that should be answered prior to starting development will help make the process more efficient and effective:

Does the assay need to simply detect the presence of the target (qualitative), or must it assign a value to the detected target (quantitative)? The development process for a qualitative or quantitative assay, although similar in many respects, ultimately will take different paths
In what type of matrix will samples be? Matrix plays an important role in both development and validation of the assay. If the assay is needed for multiple matrices (whole blood, plasma, serum, differing tissue types, etc.), each matrix must be evaluated individually to determine its impact on assay performance
Will extraction be required, and by what method? 4) What throughput will be needed?

Answering these questions early in the process will help prevent ‘reworks’ later.


Expression profiling of circulating miRNAs as a novel non-invasive diagnostic tool

Genomics, Issue 6 2011 / 13 December 2011 / Mirco Castoldi. Department of Pediatric Hematology, Oncology and Immunology University of Heidelberg

Cell-free nucleic acids circulating in human blood were first described in 19481. However, it was not until the work of Sorengon and colleagues was published in 19942 that the importance of circulating nucleic acid (cfNA) was recognised. Today, the detection of diverse type of cfNA3 in blood and other body fluids is a valuable resource for the identification of a novel biomarker4,5. Although different types of cfNA have been described (including DNA, mRNA and microRNA), this review focuses on the isolation, detection and clinical utility of circulating microRNAs.

microRNAs (miRNAs) are an abundant class of short single stranded non-coding RNAs (~22 nts) that regulate gene expression at the posttranscriptional level. Interaction between an miRNA and any given of its mRNA targets results in either translation inhibition, mRNA degradation or a combination of both mechanisms. Therefore, miRNAs activity effectively reduces the transcriptional output of a target gene, without affecting its transcription rate. Currently, the sequence of over 60,000 microRNAs are deposited in the miRBase database [Version 17, April 20116]. miRNA activity has been associated with the control of a wide range of basic processes such as development, differentiation and metabolism. Detection of differential expression of miRNAs in many cases have established the basis for miRNA functional analysis and specific miRNA expression patterns can provide valuable diagnostic and prognostic indications, for example, in the context of human malignancies7,8. Moreover, the deregulation of the expression of miRNAs has been shown to contribute to cancer development through various kinds of mechanisms, including deletions, amplification or mutations involving miRNA loci, epigenetic silencing, as well as the dysregulation of transcription factors that target specific miRNAs9,10.

Abbott logo

Abbott Receives FDA Approval for Molecular Test for Hepatitis C

Industry news, News / 18 May 2011 / Abbott

Abbott has received approval from the FDA to market its RealTime PCR test for measuring the viral load of hepatitis C…


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...